Before anything else
Merck KGaA agreed in June to buy Bio-Techne for $73 per share in cash, and the stock sits a dollar below that today. The filed numbers show a business with nearly 70% gross margins and a quarter-billion dollars of free cash flow, running flat on revenue for two years. The gap between the math and the mood has essentially closed, not because the market finally understood the business, but because a German acquirer put a number on it. The open question is what that ceiling tells us about what the business was actually worth before anyone made the call.
The claim everyone is repeating
When Bio-Techne reported its fourth-quarter fiscal 2026 results on August 12, the headline looked tidy: the company beat revenue expectations by a comfortable margin. Wells Fargo responded on August 13 by downgrading the stock from Overweight to Equal-Weight while simultaneously raising its valuation reference to match the deal price, a move that reads less like a change of view and more like an acknowledgment that the acquirer has already set the price. Benchmark reissued a hold on August 19. Every analyst reference has converged on the deal price, and the stock trades just below it.
Simply Wall St., writing on August 23, argued the stock looks overvalued based on a discounted cash flow analysis, citing a trailing price-to-earnings ratio well above the life sciences industry average. That argument made more sense before June 25. Once Merck KGaA announced the all-cash deal, the spread between the market price and the deal price typically reflects the market’s collective assessment of closing probability and timeline, a different analytical lens than pre-announcement valuation.
What the filings actually show
Strip away the deal, and the 10-K filed August 24 for the fiscal year ended June 30, 2026 describes a business in a holding pattern. Full-year net sales came in at $1.22 billion, essentially unchanged from the year before. The Protein Sciences segment, which accounts for roughly seven of every ten revenue dollars, grew slightly in reported terms but actually shrank on an organic basis, meaning after stripping out currency effects. The Diagnostics and Spatial Biology segment fell in reported terms, though its underlying organic growth was positive, a gap explained largely by currency headwinds.
The revenue stall is real, but the margin story runs in the opposite direction. The adjusted gross margin for fiscal 2026 was 69.6%, meaning that for every dollar of sales, Bio-Techne kept nearly 70 cents after the direct cost of making its products. That is the kind of margin a pharmaceutical ingredient supplier earns when its products are specialized enough that customers cannot easily substitute them. The adjusted operating margin for the full year reached just under 32%, a small improvement on the prior year but a consistent one.
Free cash flow for the year was $263 million, which is more than the company earns in net income on a GAAP basis. That gap between cash generation and reported profit is worth pausing on, because the reported earnings line has been distorted badly by one-time items in both directions over the past two years.
The earnings line that keeps changing shape
Bio-Techne’s GAAP earnings per share have swung dramatically over the past four years, from a strong result in fiscal 2022 down to near-nothing in fiscal 2025 and back up meaningfully in fiscal 2026. That is a wild ride for a business whose underlying operations barely moved. The explanation, per the company’s earnings release, is a series of non-recurring charges: an impairment on a business classified as held for sale and a non-recurring arbitration award hit fiscal 2025 hard, then partially reversed in fiscal 2026. SG&A expenses fell sharply year-over-year in fiscal 2026, almost entirely because those prior-year charges did not repeat.
The adjusted EPS figure, which strips out these one-time items, tells a quieter story: essentially flat year over year. The business, on a normalized basis, has been running in place for two years while the GAAP line lurched around beneath it. This is exactly the kind of situation where the trailing price-to-earnings ratio becomes nearly meaningless as a valuation tool. The denominator collapsed, so the ratio exploded, but the underlying earning power barely moved. The free cash flow figure is the most stable read of all.
How Bio-Techne got here
The company spent the decade before this deal building a portfolio of specialized biological research tools, the kind of reagents and instruments that academic labs and drug developers use to study proteins and cells. It paid hundreds of millions of dollars apiece for Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen, each acquisition extending its reach into higher-growth niches. The purchase of Lunaphore added microfluidic instruments for tumor analysis, pushing deeper into spatial biology, a field that maps gene activity inside tissue samples at the level of individual cells.
The revenue growth that justified those prices arrived in fiscal 2022, when sales jumped sharply and net margins hit their peak. Then the post-pandemic normalization that hit the whole life sciences tools sector hit Bio-Techne too. Growth slowed to a crawl for two consecutive years. The stock drifted down. Then Merck KGaA, the German science and technology company, looked at those 70% gross margins and that free cash flow and decided the stall was temporary. The $11.3 billion deal announced June 25 is described by FiercePharma as Merck KGaA’s largest acquisition since the Sigma-Aldrich purchase more than a decade ago.
The tension the deal does not resolve
At $73 per share, Merck KGaA is paying roughly nine times annual sales, a multiple more than twice what the broader life sciences sector trades at, per the dossier’s industry comparison. The acquirer’s price embeds an assumption that the revenue stall is temporary; the degree to which that assumption is validated will be observable in Bio-Techne’s reported results through the deal’s expected close date. Whether that assumption proves correct will be reflected in how the deal progresses through regulatory review and shareholder approval, the filed terms set the ceiling, and the spread to the current price reflects the market’s assessment of closing risk.
For anyone watching from the outside, the more instructive question is what the deal price implies about the years of premium valuation that preceded it. Bio-Techne traded at a price-to-earnings ratio well above its own decade median for most of the past decade, according to historical valuation data available via TickerScout. The acquirer’s offer is only modestly above where the stock traded before the deal was announced, suggesting the market had already priced in a recovery that the filed numbers had not yet delivered. The mood, in this case, anticipated the math. The acquirer agreed.
Reading the numbers
- $1.22 billion in net sales, fiscal year ended June 30, 2026 (10-K filed August 24). What it is: total revenue for the year. What it means here: flat for two consecutive years, a stall after a decade of growth. Everyday example: a bakery that sold $122 worth of bread last year and $122 again this year, despite opening a new pastry counter.
- 69.6% adjusted gross margin (10-K summary). What it is: the share of each sales dollar left after the direct cost of making the product. What it means here: Bio-Techne keeps nearly 70 cents of every dollar before paying for offices, salespeople, or research. Everyday example: a coffee shop that charges $5 for a latte and spends $1.52 on the beans, milk, and cup keeps $3.48 before the rent is due.
- $263 million in free cash flow (earnings release). What it is: cash generated after capital spending, the money actually available to pay down debt, buy back shares, or pay dividends. What it means here: the cash engine is running well even when the GAAP profit line is distorted by one-time charges. Everyday example: a landlord whose tax return shows a small profit after depreciation deductions but who actually deposits $2,630 more than they spend each month.
- Adjusted EPS $1.93 versus GAAP EPS $1.16 (earnings release). What it is: the gap between what the company earned after stripping out one-time items versus what accounting rules require it to report. What it means here: the GAAP figure swung from $0.46 to $1.16 in one year not because the business changed dramatically, but because large non-recurring charges in fiscal 2025 did not repeat. The adjusted figure barely moved: $1.92 to $1.93.
- $73 per share acquisition price, $11.3 billion enterprise value (FiercePharma). What it is: the agreed cash price Merck KGaA will pay for each share, and the total implied value of the business including debt. What it means here: the enterprise value is roughly nine times annual sales and more than 40 times free cash flow, a price that assumes the revenue stall ends. Everyday example: paying $400,000 for a rental property that currently earns $10,000 a year in rent, on the bet that rents will rise.
Sources
- 10-K for fiscal year ended June 30, 2026 (SEC EDGAR)
- Bio-Techne Q4 FY2026 earnings release
- TradingView: FY2026 10-K summary
- MarketBeat: analyst ratings, August 2026
- FiercePharma: Merck KGaA acquisition announcement
- Simply Wall St.: valuation commentary, August 23, 2026
- TickerScout: TECH financial data
